← Eichor
Condition: Stage Ib Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Stage Ib

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Can
Phase 3 · 49 location(s) · Dizal (Jiangsu) Pharmaceutical Co., Ltd. · NCT07182682A Study of TYK-00540 in Adult Patients With Solid Tumors
Phase 1 · 1 location(s) · TYK Medicines, Inc · NCT06246071Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastat
Phase 1/Phase 2 · 2 location(s) · Shandong Suncadia Medicine Co., Ltd. · NCT06167694Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1 · 2 location(s) · Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · NCT07156253Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
Phase 1/Phase 2 · 5 location(s) · Anbogen Therapeutics, Inc. · NCT05532696A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
Phase 1 · 3 location(s) · Proviva Therapeutics, Inc. · NCT06190886A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Backgro
Phase 1/Phase 2 · 29 location(s) · ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. · NCT07593027Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)
Phase 1/Phase 2 · 4 location(s) · Amsterdam UMC, location VUmc · NCT06384560Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcom
Phase 1/Phase 2 · 4 location(s) · Grupo Espanol de Investigacion en Sarcomas · NCT05146440A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Phase 1 · 3 location(s) · RasCal Therapeutics, Inc. · NCT04678648Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patien
Phase 1/Phase 2 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT07235176Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)
Phase 3 · 5 location(s) · Butantan Institute · NCT06891950ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06426511A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
Phase 1/Phase 2 · 1 location(s) · West China Hospital · NCT07482059A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Akeso · NCT04982276A Study of ST-1898 for Unresectable or Metastatic Melanoma
Phase 1/Phase 2 · 1 location(s) · Beijing Scitech-Mq Pharmaceuticals Limited · NCT06359860A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab a
Phase 1 · 31 location(s) · Hoffmann-La Roche · NCT05091424Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B C
Phase 1/Phase 2 · 1 location(s) · OHSU Knight Cancer Institute · NCT06249191A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220
Phase 1 · 26 location(s) · Hoffmann-La Roche · NCT05169515Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Phase 1/Phase 2 · 12 location(s) · Ascentage Pharma Group Inc. · NCT04501120Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Phase 1 · 1 location(s) · Dwight Owen · NCT06616623IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
Phase 1/Phase 2 · 1 location(s) · InxMed (Shanghai) Co., Ltd. · NCT05827796Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
Phase 1 · 1 location(s) · Fudan University · NCT06331169A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
Phase 1 · 14 location(s) · Ascentage Pharma Group Inc. · NCT04275518Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
Phase 1/Phase 2 · 7 location(s) · OriCell Therapeutics Co., Ltd. · NCT05652920Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Br
Phase 1/Phase 2 · 3 location(s) · Washington University School of Medicine · NCT06374459A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Phase 1/Phase 2 · 103 location(s) · AstraZeneca · NCT06996782Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Phase 1 · 1 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT06418061Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
Phase 1 · 1 location(s) · University of Virginia · NCT07270978PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy
Phase 1 · 1 location(s) · Michael Randall · NCT06522932
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.